866-997-4948(US-Canada Toll Free)

Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Pipeline Review, H1 2019

Published By :

Global Markets Direct

Published Date : Mar 2019

Category :

Pharmaceutical

No. of Pages : 96 Pages

Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Pipeline Review, H1 2019

Summary

Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Peroxisome proliferator-activated receptor delta is a nuclear receptor that in humans is encoded by the PPARD gene. PPAR-delta is a nuclear hormone receptor that governs a variety of biological processes and involved in the development of several chronic diseases, including diabetes, obesity, atherosclerosis, and cancer. The expression of this gene is found to be elevated in colorectal cancer cells. The elevated expression can be repressed by adenomatosis polyposis coli (APC), a tumor suppressor protein involved in the APC/beta-catenin signaling pathway.

Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) pipeline Target constitutes close to 16 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 4, 4, 2 and 3 respectively.

Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Gastrointestinal, Central Nervous System, Oncology, Genetic Disorders, Genito Urinary System And Sex Hormones, Musculoskeletal Disorders, Ophthalmology, Immunology and Respiratory which include indications Non-Alcoholic Steatohepatitis (NASH), Acute Renal Failure (ARF) (Acute Kidney Injury), Duchenne Muscular Dystrophy, Dyslipidemia, Mitochondrial Diseases, Non Alcoholic Fatty Liver Disease (NAFLD), Primary Biliary Cirrhosis, Type 2 Diabetes, Alzheimer's Disease, Bone Disorders, Bone Fracture, Colitis, Familial Chylomicronemia (Type I Hyperlipoproteinemia), Hepatocellular Carcinoma, Huntington Disease, Idiopathic Pulmonary Fibrosis, Inflammation, Keratoconjunctivitis Sicca (Dry Eye), Lebers Hereditary Optic Neuropathy (Leber Optic Atrophy), Liver Diseases, Liver Fibrosis, MELAS Syndrome (Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-Like Episodes), Metabolic Syndrome, Obesity, Osteoarthritis, Osteoporosis and Parkinson's Disease.

The latest report Peroxisome Proliferator Activated Receptor Delta - Pipeline Review, H1 2019, outlays comprehensive information on the Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD)
- The report reviews Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) targeted therapeutics and enlists all their major and minor projects
- The report assesses Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Overview
Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Companies Involved in Therapeutics Development
Chipscreen Biosciences Ltd
CymaBay Therapeutics Inc
Genfit SA
Inception Sciences Inc
Inventiva
Mitobridge Inc
Nippon Chemiphar Co Ltd
Senju Pharmaceutical Co Ltd
T3D Therapeutics Inc
Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Drug Profiles
CS-038 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Modulate PPAR-Delta for Metabolic and Musculoskeletal Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
elafibranor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fonadelpar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HPP-593 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lanifibranor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MA-0204 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MA-0211 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MA-0217 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NC-2400 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
seladelpar lysine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize PPAR Delta for Mitochondrial Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize PPARA and PPARD for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize PPAR-delta for Non-Alcoholic Steatoheptatis and Obesity - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit PPAR Beta and PPAR Delta for Metabolic Disorders, Inflammatory Diseases and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
T-3D959 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Dormant Products
Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Discontinued Products
Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Product Development Milestones
Featured News & Press Releases
Mar 12, 2019: Genfit to study elafibranor in Phase II trial for paediatric NASH
Feb 21, 2019: Inventiva announces further progress achieved in the clinical development of lanifibranor for the treatment of NASH
Feb 19, 2019: CymaBay Therapeutics announces early enrollment of a phase 2b study of seladelpar in patients with nonalcoholic steatohepatitis
Feb 19, 2019: Inventivas lanifibranor fails to meet endpoint in FASST trial
Feb 15, 2019: CymaBay Therapeutics announces seladelpar granted breakthrough therapy designation by the FDA for the treatment of primary biliary cholangitis
Feb 04, 2019: INVENTIVA : New results on lanifibranor to be presented at the International Liver Congress 2019
Dec 17, 2018: GENFIT: Positive 30-month DSMB recommendation for continuation of phase 3 RESOLVE-IT study of Elafibranor in NASH
Dec 06, 2018: GENFIT: Positive phase 2 results from study of Elafibranor in primary biliary cholangitis
Nov 13, 2018: Cymabay Therapeutics presents positive results from its ongoing phase 2 study of Seladelpar in patients with PBC at The Liver Meeting 2018
Oct 30, 2018: Cymabay announces the initiation of the Seladelpar global phase 3 registration study (enhance) for the treatment of primary biliary cholangitis and additional corporate updates
Oct 15, 2018: Inventiva announces last visit by last patient in its phase IIb SSC trial and second positive DSMB review in its phase IIbnash trial with Lanifibranor
Oct 10, 2018: Inventiva Announces Two Poster Presentations at the American College of Rheumatology Conference
Oct 03, 2018: Cymabay Therapeutics announces additional positive results from its ongoing phase 2 study of Seladelpar in patients with PBC will be presented during the late-breaking session at the liver meeting
Oct 02, 2018: GENFIT: New data to be presented at 2018 AASLD meeting, ahead of key results expected in 2018 and 2019
Aug 31, 2018: GENFIT announces its upcoming participation in a number of investor and NASH-specific events over the next two months
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Indications, H1 2019
Number of Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019
Number of Products under Investigation by Universities/Institutes, H1 2019
Products under Investigation by Universities/Institutes, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Pipeline by Chipscreen Biosciences Ltd, H1 2019
Pipeline by CymaBay Therapeutics Inc, H1 2019
Pipeline by Genfit SA, H1 2019
Pipeline by Inception Sciences Inc, H1 2019
Pipeline by Inventiva, H1 2019
Pipeline by Mitobridge Inc, H1 2019
Pipeline by Nippon Chemiphar Co Ltd, H1 2019
Pipeline by Senju Pharmaceutical Co Ltd, H1 2019
Pipeline by T3D Therapeutics Inc, H1 2019
Dormant Products, H1 2019
Discontinued Products, H1 2019

List of Figures
Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Top 10 Indications, H1 2019
Number of Products by Mechanism of Actions, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Routes of Administration, H1 2019
Number of Products by Stage and Routes of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *